文献速递前列腺癌

基于多参数MRI的主动监测四年结局:PSA动态与系列MRI可省略方案活检

Four-year outcomes from a multiparametric magnetic resonance imaging (MRI)-based active surveillance programme: PSA dynamics and serial MRI scans allow omission of protocol biopsies.
PubMed 文献 · BJU Int · 2018-10-09

该研究报道了基于多参数MRI的主动监测方案(首次确认性活检后不再进行方案活检)的四年结局。211例因PSA升高诊断为Gleason 3+3前列腺癌的患者纳入分析,中位随访4.2年。结果显示,初始MRI可见病灶者进展至根治性治疗的风险显著高于初始MRI阴性者(37.6% vs 12.8%),初始MRI阴性者中PSA速度与后续进展显著相关,而首次MRI高风险可见病灶者即使继续主动监测仍有较高进展风险。

要点

  • 初始MRI阴性且确认性活检未升级者,可安全省略方案活检,采用PSA和MRI监测。
  • 初始MRI可见病灶者进展至根治性治疗风险显著增高,需更密切监测。
  • 初始MRI阴性者中PSA速度与后续进展显著相关,可辅助风险分层。

核心结论

  • 低危Gleason 3+3前列腺癌主动监测患者可省略方案活检,代之以MRI和PSA监测及选择性再活检。

研究设计与样本

  • 前瞻性临床数据库研究,纳入211例因PSA升高诊断为Gleason 3+3前列腺癌且诊断后接受mpMRI的患者,中位随访4.2年。

主要发现

  • 初始MRI可见病灶者进展至根治性治疗率为47/125(37.6%),初始MRI阴性者为11/86(12.8%),比值比4.1(95%CI 2.0-8.5),P<0.001。
  • 初始MRI阴性且接受确认性系统活检的56例中,仅1例(1.8%)升级为Gleason 3+4。
  • 初始MRI阴性者中,PSA速度与后续进展显著相关,曲线下面积0.85(95%CI 0.75-0.94),P<0.001。
  • 首次MRI高风险可见病灶且继续主动监测者,后续进展率为19/76(25.0%),无可见病灶者为9/84(10.7%)。

临床怎么用

  • 对初始MRI阴性且确认性活检无升级的低危Gleason 3+3患者,可省略方案活检,采用PSA动态和系列MRI监测。
  • 初始MRI可见病灶者应视为进展高风险人群,需加强监测并及时评估根治性治疗指征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To report outcomes from a multiparametric (mp) magnetic resonance imaging (MRI)-based active surveillance programme that did not include performing protocol biopsies after the first confirmatory biopsy. PATIENTS AND METHODS: All patients diagnosed with Gleason 3 + 3 prostate cancer because of a raised PSA level who underwent mpMRI after diagnosis were included. Patients were recorded in a prospective clinical database and followed up with PSA monitoring and repeat MRI. In patients who remained on active surveillance after the first MRI (with or without confirmatory biopsy), we investigated PSA dynamics for association with subsequent progression. Comparison between first and second MRI scans was undertaken. Outcomes assessed were: progression to radical therapy at first MRI/confirmatory biopsy and progression to radical therapy in those who remained on active surveillance after first MRI. RESULTS: A total of 211 patients were included, with a median of 4.2 years of follow-up. The rate of progression to radical therapy was significantly greater at all stages among patients with visible lesions than in those with initially negative MRI (47/125 (37.6%) vs 11/86 (12.8%); odds ratio 4.1 (95% CI 2.0-8.5), P < 0.001). Only 1/56 patients (1.8%) with negative initial MRI scans who underwent a confirmatory systematic biopsy had upgrading to Gleason 3 + 4 disease. PSA velocity was significantly associated with subsequent progression in patients with negative initial MRI (area under the curve 0.85 [95% CI 0.75-0.94]; P <0.001). Patients with high-risk visible lesions on first MRI who remained on active surveillance had a high risk of subsequent progression 19/76 (25.0%) vs 9/84 (10.7%) for patients with no visible lesions, despite reassuring targeted and systematic confirmatory biopsies and regardless of PSA dynamics. CONCLUSION: Men with low-risk Gleason 3 + 3 prostate cancer on active surveillance can forgo protocol biopsies in favour of MRI and PSA monitoring with selective re-biopsy.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Gallagher KM, Christopher E, Cameron AJ, et al. Four-year outcomes from a multiparametric magnetic resonance imaging (MRI)-based active surveillance programme: PSA dynamics and serial MRI scans allow omission of protocol biopsies. BJU Int. 2018. PMID: 30113755. doi:10.1111/bju.14513

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。